CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤免疫治疗的未来
英文原题：The Future of Cancer Immunotherapy.
查看英文原题
The Future of Cancer Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本文介绍三种新兴癌症免疫疗法：双特异性T细胞衔接器（BiTE）、TIL（肿瘤浸润淋巴细胞）疗法和癌症疫苗。这些疗法可识别癌细胞上的特定靶点并触发特异性免疫应答。迄今并非所有肿瘤类型都能从这些方法中获益；目前最佳疗效见于血液系统恶性肿瘤、黑色素瘤和肺癌。瑞士多个癌症中心目前正在测试这些新型生物制品，临床医生应熟悉相关治疗流程，因为未来近期内可能会有患者接受此类疗法。
展开英文摘要原文
This article describes three emerging, novel cancer immunotherapies: BITE, TIL and cancer vaccines are therapies that recognize specific targets on cancer cells and trigger a specific immune response. So far, not all tumor types can benefit from these approaches the best results have been observed in hematological malignancies, melanoma, and lung cancer.
These novel biological products are currently being tested in several cancer centers in Switzerland, and physicians must be familiar with these procedures, as some of their patients might be treated with such therapies in the near future.
论文信息
- 作者
- Mach N
- 单位
- Clinical Research Unit, Oncology Dpt, Hôpitaux Universitaires de Genève, Geneva, Switzerland.Switzerland
- 期刊
- Praxis2023
- 原文标识
- PubMed 36855886 · DOI 10.1024/1661-8157/a003975